ライフサイエンスコーパス: methylprednisolone

1 te outbreak due to injection of contaminated methylprednisolone.

2 ne or in combination with the corticosteroid methylprednisolone.

3 unosuppressed after MI with cyclosporine and methylprednisolone.

4 in inhibitor, short-course methotrexate, and methylprednisolone.

5 or 3 days or placebo as an add-on therapy to methylprednisolone.

6 anti-CD52 monoclonal antibody alemtuzumab or methylprednisolone.

7 those resulting from treatment with topical methylprednisolone.

8 oval of doxycycline and were unresponsive to methylprednisolone.

9 blinding, and directly compared Hyalgan with methylprednisolone.

10 hromatography for levels of prednisolone and methylprednisolone.

11 renal failure when compared with intravenous methylprednisolone.

12 Acute rejection and SCAR were treated by methylprednisolone.

13 hemotherapy, and 2 improved with intravenous methylprednisolone.

14 bclinical rejections were treated with bolus methylprednisolone.

15 cultures from FIV-infected cats treated with methylprednisolone.

16 andomly assigned: 30 to gentamicin and 30 to methylprednisolone.

17 5-2005, Leiden cohort, n = 153) treated with methylprednisolone.

18 ng pain following injections of contaminated methylprednisolone.

19 ns associated with injection of contaminated methylprednisolone.

20 he number of emergency visits and dosages of methylprednisolone.

21 buted to epidural injections of contaminated methylprednisolone.

22 5% and 16 patients were treated with topical methylprednisolone 0.5% twice daily for 10 weeks, in add

23 High concentrations of methylprednisolone (0.32 mg/mL) accelerated growth and a

24 /6 mice, without or with topical therapy, 1% methylprednisolone, 0.025% doxycycline, or physiologic s

25 opical formulations containing 5% IL-1Ra, 1% methylprednisolone, 0.05% cyclosporin A, and a vehicle c

26 f the patients were treated with intravenous methylprednisolone 1 g daily for 3 days and then tapered

27 We suggest the use of IV methylprednisolone 1 mg/kg/day in patients with early mo

28 e prospectively randomized to receive either methylprednisolone 1,000 mg followed by a 3-month steroi

29 After treatment with high-dose methylprednisolone (1 g/day, intravenously, for 3-5 days

30 Group A received pre-CPB intravenous methylprednisolone (1 mg/kg) plus four additional intrav

31 or =60 mg/day for > or =2 months), and pulse methylprednisolone (1,000 mg intravenously for 1-3 days)

32 o +3 with dose adjusted by blood levels, and methylprednisolone (15 mg/kg day 0 to +3).

33 lind, placebo-controlled study to receive IV methylprednisolone (15 mg/kg of ideal body weight/day) o

34 lly numbered envelopes to receive placebo or methylprednisolone 16 mg/kg/day (</=1000 mg) for 3 days.

35 Patients were randomized to receive methylprednisolone 2 mg/kg per day plus etanercept, myco

36 ght atriotomy with antiinflammatory therapy (methylprednisolone 2 mg/kg per day) (antiinflammatory gr

37 ion at the site of injection of contaminated methylprednisolone, 21% had an abnormal MRI, and all but

38 of cardiopulmonary bypass to receive either methylprednisolone (250 mg at anaesthetic induction and

39 /kg), antithymocyte globulin (90 mg/kg), and methylprednisolone (3 mg/kg).

40 mbination including IVIG 1 g/kg, intravenous methylprednisolone 30 mg/kg, Vinca alkaloids (VCR 0.03 m

41 ere randomly assigned to receive intravenous methylprednisolone, 30 mg per kilogram of body weight (1

42 reduction; P = 0.02), but was marginal with methylprednisolone (32% reduction; P = 0.06).

43 pants were randomized to receive intravenous methylprednisolone (4 mg/kg/d for 2 weeks) and oral pred

44 mization, patients in the VSE group received methylprednisolone (40 mg) and patients in the control g

45 groups (37 patients each) received 80 mg of methylprednisolone, 40 mg of methylprednisolone, or plac

46 surgery were 73%, 81%, and 92% in the 80-mg methylprednisolone, 40-mg methylprednisolone, and placeb

47 Corticosteroid therapy consisted of either methylprednisolone, 500 mg intravenously for 3 days, or

48 (1:1) by a block design to two intratympanic methylprednisolone (62.5 mg/mL) or gentamicin (40 mg/mL)

49 In addition, methylprednisolone (a synthetic glucocorticoid) treatmen

50 A 3-day course of methylprednisolone accompanied gene transfer without fur

51 ecrosis of the femoral head induced by depot methylprednisolone acetate (depomedrol).

52 third-stage larvae and treated for 6 wk with methylprednisolone acetate (MPA), a synthetic glucocorti

53 fections linked to injection of contaminated methylprednisolone acetate (MPA).

54 gitis among patients exposed to contaminated methylprednisolone acetate (MPA).

55 meningitis due to injections of contaminated methylprednisolone acetate can present with vascular seq

56 0 units daily for 3 days and 1gr intravenous methylprednisolone acetate for 3 days followed by 1 mg/k

57 fungal outbreak associated with contaminated methylprednisolone acetate injections.

58 ucocorticoid injections of preservative-free methylprednisolone acetate prepared by a single compound

59 ingitis linked to contaminated injections of methylprednisolone acetate produced by the New England C

60 ssociated with the injection of contaminated methylprednisolone acetate produced by the New England C

61 However, coadministration of methylprednisolone acetate results in robust hyphal tiss

62 ociated with injections of preservative-free methylprednisolone acetate that was purchased from a sin

63 ll persons potentially exposed to implicated methylprednisolone acetate was conducted by federal, sta

64 Three lots of methylprednisolone acetate were recalled by the pharmacy

65 Contamination of methylprednisolone acetate with the black mold, Exserohi

66 d rabbits (treated with weekly injections of methylprednisolone acetate).

67 Methylprednisolone acetate, a long-acting glucocorticoid

68 r joint injections with contaminated lots of methylprednisolone acetate.

69 of 1 injection (range, 1 to 6) of implicated methylprednisolone acetate.

70 of fungal meningitis related to contaminated methylprednisolone acetate.

71 50 mg of cyclophosphamide, and 100-250 mg of methylprednisolone, administered on 2 occasions 2 weeks

72 Prolonged methylprednisolone administration accelerated the resolu

73 cocorticoid resistance and whether prolonged methylprednisolone administration accelerates the suppre

74 into a randomized trial evaluating prolonged methylprednisolone administration in unresolving ARDS ha

75 There were no SAEs clearly related to methylprednisolone administration, and methylprednisolon

76 ntinued to show superior efficacy over pulse methylprednisolone alone for treatment of lupus nephriti

77 with simvastatin alone or with high dose of methylprednisolone alone or in combination with simvasta

78 4 T cells, CD8 T cells, and NK cells or with methylprednisolone alone.

79 Treatment of mdx myotubes with a pro-drug of methylprednisolone also reduced calpain substrate hydrol

80 re tested: (1) low-dose cyclophosphamide and methylprednisolone and (2) fludarabine.

81 as greater in patients who received 80 mg of methylprednisolone and 40 mg of methylprednisolone than

82 Rats treated concomitantly with methylprednisolone and a broad-spectrum matrix metallopr

83 0-increased MMP-9 secretion was inhibited by methylprednisolone and also by compound A, a novel nonst

84 BALB/c mice underwent immunosuppression with methylprednisolone and antibodies specific for CD4 T cel

85 After immunosuppression with methylprednisolone and antibodies, EA and beta-gal were

86 isk factor that was independent of augmented methylprednisolone and donor seropositivity.

87 The choice between methylprednisolone and gentamicin should be made based o

88 7-5.24), and treatment with a combination of methylprednisolone and intravenous immunoglobulin (OR 2.

89 The most common safety outcomes in the methylprednisolone and placebo group were infection (465

90 Treatment with methylprednisolone and several broad-spectrum MMPIs, inc

91 completely after treatment with intravenous methylprednisolone and topical tacrolimus and clobetasol

92 steroids (betamethasone, triamcinolone, and methylprednisolone) and three local anesthetics (lidocai

93 ression with 200 mg/kg cyclophosphamide, 1 g methylprednisolone, and 90 mg/kg equine antithymocyte gl

94 nary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor a

95 tial adjuncts, prostacyclin (PGI2), heparin, methylprednisolone, and eptifibatide (a GPIIb/IIIa antag

96 d 92% in the 80-mg methylprednisolone, 40-mg methylprednisolone, and placebo groups, respectively.

97 l, other particulate steroids (prednisolone, methylprednisolone, and triamcinolone) caused often imme

98 d only after treatment with 5% IL-1Ra and 1% methylprednisolone, and were absent after cyclosporin A

99 Although methylprednisolone appears to be safe, it did not provid

100 he combination of pulse cyclophosphamide and methylprednisolone appears to provide additional benefit

101 d dexamethasone, spironolactone, and 6-alpha-methylprednisolone as major contributors to corticostero

102 Group I was given 250 mg i.v. methylprednisolone at 1 and 6 hr, and group II received

103 All patients were treated with methylprednisolone at 2 mg/kg/day, but failed to respond

104 Methylprednisolone at a dose of 2 mg/kg or daily equival

105 Intravenous methylprednisolone at a standard anti-inflammatory dose

106 the study; IOP increased significantly with methylprednisolone at week 10 (P = 0.04).

107 HR consisted of a methylprednisolone bolus and infusions of vasopressin an

108 Hormonal resuscitation consisted of a methylprednisolone bolus and infusions of vasopressin an

109 CV infection (hazard ratio 2.5, P=0.001) and methylprednisolone boluses (hazard ratio 1.09 per bolus,

110 HCV infection and methylprednisolone boluses were found to be independent

111 on days 0 and 4 postoperatively, preceded by methylprednisolone boluses.

112 Glucocorticoids, including dexamethasone, methylprednisolone, budesonide, and fluticasone, potenti

113 udy period was observed in rats treated with methylprednisolone but not in rats treated with cyclopho

114 Concomitant use of cyclosporin A or methylprednisolone, but not rapamycin or mycophenolate,

115 High-dose methylprednisolone cannot be justified as a standard tre

116 er one cycle of chemotherapy with etoposide, methylprednisolone, cisplatin, and cytarabine in patient

117 At 3 mo, 33 (49%) of 67 after intravenous methylprednisolone compared with 48 (69%) or 70 after pl

118 tial inflammatory response, the acute use of methylprednisolone compared with placebo decreased treat

119 Methylprednisolone, compared with placebo, did not reduc

120 spinal cord injury is controversial; however methylprednisolone continues to be widely employed in th

121 lprednisolone or conventional nutrition plus methylprednisolone (controls).

122 Exposure to methylprednisolone could enhance the virulence of E. ros

123 Rats treated with 2 mg/kg of methylprednisolone daily for 1, 2, or 4 weeks had an inc

124 ejection episodes were treated with 1.0 g of Methylprednisolone daily for 3 consecutive days.

125 On days 3 and 7, methylprednisolone decreased interleukin-6 and increased

126 Methylprednisolone decreased interleukin-6 by days 3 and

127 The glucocorticoids methylprednisolone, deflazacort, and prednisone increase

128 Methylprednisolone did not have a significant effect on

129 As compared with placebo, methylprednisolone did not increase the rate of infectio

130 te rejection or antirejection treatment with methylprednisolone did not increase the risk of BKV repl

131 ed to methylprednisolone administration, and methylprednisolone did not increase viral load.

132 cretion of nasal polyp patients treated with methylprednisolone, doxycycline, anti-IL-5, or placebo.

133 N), number of emergency visits and dosage of methylprednisolone during a 16-week period were compared

134 allograft had a lower risk of resistance to methylprednisolone during AR (odds ratio, 0.29; 95% conf

135 essors, combined vasopressin-epinephrine and methylprednisolone during CPR and stress-dose hydrocorti

136 nistration of a 3-day regimen of intravenous methylprednisolone either in an outpatient clinic (n=69)

137 L exposed to plasma samples collected during methylprednisolone exhibited significant progressive inc

138 Both groups received 3 days of pulse methylprednisolone followed by a tapering course of oral

139 Treatment with methylprednisolone for 1 wk (n = 8) at 4 wk after immuni

140 ents were initially commenced on intravenous methylprednisolone for 3 days, followed by oral predniso

141 ne sodium succinate equivalent to 1000 mg of methylprednisolone for 5 days, 0.4 mg/kg/d of intravenou

142 ostratum conidia preexposed to 0.32 mg/mL of methylprednisolone for 7 days in immunocompetent flies l

143 a short course of corticosteroids (1 mg/d of methylprednisolone for about 2 weeks).

144 ients in TAC/MMF and 20% in TAC/SRL received methylprednisolone for acute rejection/SCAR.

145 ch, we evaluated the efficacy of intravenous methylprednisolone for HCPS treatment, through a paralle

146 Our results do not support the use of methylprednisolone for HCPS.

147 Patients were treated with alemtuzumab and methylprednisolone for induction, followed by tacrolimus

148 d a history of epidural spinal injections of methylprednisolone for low back pain.

149 Subjects received concurrent 2 mg/kg per day methylprednisolone for more than or equal to 10 days.

150 RS trial does not support the routine use of methylprednisolone for patients undergoing cardiopulmona

151 se results do not support the routine use of methylprednisolone for persistent ARDS despite the impro

152 Controls included patients receiving methylprednisolone for rejection (n=4), two adults with

153 or paraspinal glucocorticoid injection with methylprednisolone from a single compounding pharmacy.

154 None responded to methylprednisolone, given for a minimum of 3 days.

155 ss treatment failure among patients from the methylprednisolone group (8 patients [13%]) compared wit

156 on) and from 16.4 (12.5) to 1.6 (3.4) in the methylprednisolone group (90% reduction; mean difference

157 0.3 to 38.6 percent) and 29.2 percent in the methylprednisolone group (95 percent confidence interval

158 of 67 and 32 of 67 (48%) in the intravenous methylprednisolone group and 51 (73%) of 70 and 35 of (5

159 lycemia occurred in 11 patients (18%) in the methylprednisolone group and in 7 patients (12%) in the

160 etween the 2 groups (6 patients [10%] in the methylprednisolone group vs 9 patients [15%] in the plac

161 atients in the gentamicin group vs 15 in the methylprednisolone group).

162 ation therapy (P = 0.002) groups than in the methylprednisolone group.

163 tient in the gentamicin group and two in the methylprednisolone group.

164 ree in the gentamicin group and three in the methylprednisolone group.

165 surgery incorporated, both the 80- and 40-mg methylprednisolone groups had lower likelihood of surger

166 thylprednisolone, </=240 mg/d) or high-dose (methylprednisolone, >240 mg/d) groups based on CS dosage

167 ving placebo, patients receiving intravenous methylprednisolone had a somewhat shorter initial period

168 Patients treated with methylprednisolone had progressive and sustained reducti

169 Injection of contaminated methylprednisolone has resulted in an unprecedented nati

170 SHAP (Adriamycin = doxorubicin, Solumedrol = methylprednisolone, High-dose Ara-C = cytosine arabinosi

171 nance tacrolimus, mycophenolate mofetil, and methylprednisolone immunosuppression.

172 Methylprednisolone in a dose of 1 mg x kg(-1) x day(-1)

173 dy was developed to evaluate alemtuzumab and methylprednisolone in combination.

174 mus and mycophenolate in all three arms, and methylprednisolone in groups A and C only (standard clin

175 ARDS Network currently is testing the use of methylprednisolone in late ARDS.

176 ficial effect of pulse high-dose intravenous methylprednisolone in patients with allergic bronchopulm

177 Topical tacrolimus was more effective than methylprednisolone in reducing the CFS score at week 10

178 exchange was more effective than intravenous methylprednisolone in the achievement of renal recovery

179 us (SLE) was the use of cyclophosphamide and methylprednisolone in the treatment of lupus nephritis.

180 Treatment with methylprednisolone increased disease severity in infecte

181 flow cytometry, and ELISA demonstrated that methylprednisolone increased the expression of miRNA-98

182 Methylprednisolone increased the number of ventilator-fr

183 adult rats with the antiinflammatory steroid methylprednisolone increases the activity of matrix meta

184 Early methylprednisolone infusion (n = 55) compared with place

185 cluded rituximab infusions, cyclophosphamide/methylprednisolone infusions, prednisone and mycophenola

186 ventions included mechanical ventilation and methylprednisolone infusions.

187 d thrombin-induced platelet aggregation, and methylprednisolone inhibited ADP-induced aggregation to

188 received 4 doses over 14 days of 40 mg/mL of methylprednisolone injected into the middle ear.

189 to those that led the patient to undergo the methylprednisolone injection.

190 chronic tension-type headaches per month vs methylprednisolone injections (SMD, -2.5; 95% CI, -3.5 t

191 Methylprednisolone injections are a non-ablative, effect

192 Methylprednisolone injections for CTS have significant b

193 ungal infections as a result of contaminated methylprednisolone injections.

194 re treated with intraarticular injections of methylprednisolone into all joints with clinical synovit

195 early intervention (EI) with intraarticular methylprednisolone into all synovitic joints or to conse

196 e, it has been clinical dogma that high-dose methylprednisolone is beneficial in the treatment of opt

197 Patients were grouped into lower-dose (methylprednisolone, </=240 mg/d) or high-dose (methylpre

198 Each group received daclizumab induction and methylprednisolone maintenance.

199 , and tacrolimus, mycophenolate mofetil, and methylprednisolone maintenance.

200 , and tacrolimus, mycophenolate mofetil, and methylprednisolone maintenance.

201 le (a glutamate release inhibitor, 8 mg/kg), methylprednisolone (MP 30 mg/kg) or both.

202 Patients received 30 mg/kg of methylprednisolone (MP) (n = 77) or placebo (n = 76) pre

203 Patients were randomly assigned to methylprednisolone (MP) 16 mg twice daily or placebo (PL

204 0 patients with AR received immediate pulsed methylprednisolone (MP) and one untreated patient develo

205 The use of methylprednisolone (MP) and other corticosteroids for th

206 loped an animal model that demonstrates that methylprednisolone (MP) can block PV IgG-induced acantho

207 In young swine, the administration of methylprednisolone (MP) during the standard tolerance-in

208 microg/ml doxycycline, or LPS with 0.1 mg/ml methylprednisolone (MP) for 24 hours.

209 Glucocorticoids such as methylprednisolone (MP) have been used as analgesic and

210 closporine-A (CsA) and the anti-inflammatory methylprednisolone (MP) in a stroke model.

211 ls from healthy donors were exposed to 1 muM methylprednisolone (MP) in vitro and then subjected to m

212 Although methylprednisolone (MP) is currently the standard therap

213 Methylprednisolone (MP) is the only therapeutic agent ap

214 Methylprednisolone (MP) is used to treat a variety of ne

215 ) promote recovery in animal models, whereas methylprednisolone (MP) promotes neurological recovery i

216 rt 1, matched unrelated donor transplant and methylprednisolone (MP) T-cell depletion (TCD) of donor

217 d to compare preoperative and intraoperative methylprednisolone (MP) to intraoperative MP alone with

218 tions following spinal cord injury (SCI) and methylprednisolone (MP) treatment of SCI.

219 Methylprednisolone (MP), a synthetic glucocorticoid agon

220 Cyclosporin A (CSA), methylprednisolone (MP), methotrexate (MTX), and mycophe

221 atients, who received cyclosporine (CSA) and methylprednisolone (MP), were matched for age, diagnosis

222 was superior to a 5-fold higher dose of free methylprednisolone (MP).

223 ized controlled trial of tri-iodothyronine+/-methylprednisolone [MP] therapy) undergoing PAC-guided a

224 following treatment with the corticosteroid methylprednisolone (MPL).

225 travenous bolus of 0.5 mg/kg per 12 hours of methylprednisolone (n = 61) or placebo (n = 59) for 5 da

226 exchanges (n = 70) or 3000 mg of intravenous methylprednisolone (n = 67).

227 e for all 7507 patients randomly assigned to methylprednisolone (n=3755) and to placebo (n=3752).

228 Proadrenomedullin levels were decreased with methylprednisolone on day 3 in patients with infectious

229 Protein C levels were increased with methylprednisolone on days 3 and 7 in patients with infe

230 Evaluate the effects of methylprednisolone on markers of inflammation, coagulati

231 fect of donor treatment with simvastatin and methylprednisolone on microvascular dysfunction and immu

232 In CRSwNP patients, treatment with methylprednisolone or anti-IL-5 resulted in the reductio

233 ived either intensive enteral nutrition plus methylprednisolone or conventional nutrition plus methyl

234 ent of EDE with the anti-inflammatory agents methylprednisolone or doxycycline preserves apical corne

235 Treatment of EDE with methylprednisolone or doxycycline reduced corneal permea

236 s were given aggressive therapy (intravenous methylprednisolone or oral prednisone 5-30 mg/kg/day; n

237 least seven days' duration to receive either methylprednisolone or placebo in a double-blind fashion.

238 The DA rats received simvastatin, methylprednisolone, or both 2 hr before heart donation.

239 Mice were treated daily with dexamethasone, methylprednisolone, or PBS from days 0 to 14 or days 10

240 ceived 80 mg of methylprednisolone, 40 mg of methylprednisolone, or placebo.

241 s treated with pulse cyclophosphamide, pulse methylprednisolone, or the combination of both.

242 Results With prednisolone, methylprednisolone, or triamcinolone, blood flow was rap

243 pical treatment with 5% IL-1Ra (P < .01), 1% methylprednisolone (P < .01), and 0.05% cyclosporin A (P

244 0.04), and to have been treated with pulsed methylprednisolone (P = 0.03).

245 y inhibited by 74% and 90% after exposure to methylprednisolone (P<0.05), 11% and 24% after exposure

246 antly in both groups (tacrolimus, P = 0.003; methylprednisolone, P = 0.008), whereas HLA-DR expressio

247 Splenectomized animals were given 10 mg of methylprednisolone per ml at the time of inoculation.

248 atment with high-dose pulse intravenous (IV) methylprednisolone permits a shorter course of therapy.

249 As compared with intravenous methylprednisolone, plasma exchange was associated with

250 tions supported by phase II clinical trials (methylprednisolone plus alemtuzumab or ibrutinib) seem b

251 ur doses, MMF was given orally at 3 g/d, and methylprednisolone/prednisone was given at 7 mg/kg per d

252 ylprednisolone premedication, or intravenous methylprednisolone premedication plus oral prednisone fo

253 either placebo glucocorticoids, intravenous methylprednisolone premedication, or intravenous methylp

254 ular RhoA GTPase pathway activation, whereas methylprednisolone prevented activation of innate immune

255 reatment in combination with simvastatin and methylprednisolone prevents IRI and has beneficial effec

256 ngal meningitis associated with contaminated methylprednisolone produced by a compounding pharmacy ha

257 more aggressive approaches such as high-dose methylprednisolone pulse therapy are used to provide tra

258 lative glucocorticoid doses (daily dose plus methylprednisolone pulse) during the first 6 months both

259 ections (cRR, 0.05 [0.02-0.6]; P = 0.01) and methylprednisolone pulses negatively affected the outcom

260 ympanic administration of the corticosteroid methylprednisolone reduces vertigo compared with gentami

261 were desmopressin use, triiodothyronine and methylprednisolone replacement, fluid management, vasopr

262 steroid injections (ESIs) with contaminated methylprednisolone resulted in an outbreak of fungal men

263 cute rejections: the fourth was treated with methylprednisolone, rituximab, and immunoglobulin.

264 CI, 1.44-7.59; P<0.001), and treatment with methylprednisolone (RR, 2.31; 95% CI, 1.07-4.94; P=0.03)

265 alone or in combination with simvastatin and methylprednisolone significantly reduced cardiac troponi

266 With initial methylprednisolone sodium succinate and alternate treatm

267 ppressive therapy, consisting of intravenous methylprednisolone sodium succinate equivalent to 1000 m

268 She was treated with methylprednisolone sodium succinate, plasma exchange, an

269 Previous studies showed that methylprednisolone specifically increased Na(+)/H(+) exc

270 lly administration of levothyroxine (T4) and methylprednisolone (steroid, i.e., the "T4 Protocol") in

271 ely used therapies such as pulse intravenous methylprednisolone still need to be addressed.

272 sion treatment with antithymyocyte globulin, methylprednisolone, tacrolimus, mycophenolate mofetil, a

273 ved 80 mg of methylprednisolone and 40 mg of methylprednisolone than in those who received placebo (d

274 Despite infusions of methylprednisolone, the patient expired on hospital day

275 In addition, starting methylprednisolone therapy more than two weeks after the

276 Methylprednisolone therapy was associated with greater i

277 elevated but not differentially affected by methylprednisolone therapy.

278 and laboratory investigation and a trial of methylprednisolone therapy.

279 nt (placebo, oral prednisone, or intravenous methylprednisolone), time, and treatment x time interact

280 The addition of methylprednisolone to antibody therapy correlated with i

281 ition of a single pulsed dose of intravenous methylprednisolone to conventional intravenous immune gl

282 etermine whether the addition of intravenous methylprednisolone to conventional primary therapy for K

283 Two non-responders switched from methylprednisolone to gentamicin.

284 e hypothesis of inferiority of intratympanic methylprednisolone to oral prednisone for primary treatm

285 voked potentials were slow to develop in the methylprednisolone-treated cats.

286 of 30 placebo-treated patients and 11 of 30 methylprednisolone-treated patients progressed to the pr

287 Corneas of immunocompetent, methylprednisolone-treated, and cyclophosphamide-treated

288 renomedullin levels were lower by day 3 with methylprednisolone treatment (p = .004).

289 Short-term pre-CPB and post-CPB methylprednisolone treatment may complicate PPS.

290 Methylprednisolone treatment of cats with established FI

291 id, and the particulate steroids cortivazol, methylprednisolone, triamcinolone, and prednisolone.

292 .21, 0, and 0 capillaries per millimeter for methylprednisolone, triamcinolone, or prednisolone, resp

293 iratory distress syndrome, administration of methylprednisolone was associated with improvement in im

294 h anti-CD154 mAb, mycophenolate mofetil, and methylprednisolone was associated with persistently low

295 Methylprednisolone was associated with significantly inc

296 eceived placebo, those who received 80 mg of methylprednisolone were less likely to have surgery (odd

297 The number of emergency visit and doses of methylprednisolone were significantly reduced compared t

298 Administration of methylprednisolone, which has become common practice in

299 e patient responded to high-dose intravenous methylprednisolone, which resulted in improvement of ren

300 -1.47), and two large trials of intravenous methylprednisolone with altogether 467 participants, in